News Archive

The Lung-MAP trial is important in two ways. It uses genomic information to assign patients to an investigational therapy and it brings together key stakeholders – industry, academia, advocacy and government – to advance precision medicine research and development. Pfizer is proud to be part of this important collaboration, which has the potential to make a significant impact on the future of oncology drug development and, most important, lead to more effective treatment options for patients with lung cancer.